| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
31.91(B) |
| Last
Volume: |
729,712 |
Avg
Vol: |
746,298 |
| 52
Week Range: |
$146.93 - $300.55 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 529 |
| Guru Rank Value : 3.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
41,162 |
119,808 |
276,786 |
379,290 |
| Total Sell Value |
$10,986,875 |
$32,786,879 |
$70,049,593 |
$87,762,933 |
| Total People Sold |
6 |
7 |
9 |
12 |
| Total Sell Transactions |
21 |
30 |
43 |
61 |
| End Date |
2025-02-02 |
2024-11-01 |
2024-05-03 |
2023-05-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-24 |
4 |
AS |
$300.00 |
$1,633,500 |
D/D |
(5,445) |
20,221 |
|
-11% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-24 |
4 |
OE |
$42.22 |
$229,888 |
D/D |
5,445 |
25,666 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2025-03-24 |
4 |
AS |
$299.00 |
$2,224,560 |
D/D |
(7,440) |
136 |
|
-11% |
|
| Pyott David E I |
Director |
– • – |
2025-03-24 |
4 |
OE |
$88.95 |
$661,788 |
D/D |
7,440 |
7,576 |
|
- |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-21 |
4 |
AS |
$285.00 |
$1,231,485 |
D/D |
(4,321) |
20,221 |
|
-8% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-04 |
4 |
AS |
$239.25 |
$194,766 |
D/D |
(808) |
24,542 |
|
7% |
|
| Fitzgerald Kevin Joseph |
CSO & EVP, Head of Research |
• – – |
2025-03-04 |
4 |
AS |
$239.24 |
$203,532 |
D/D |
(844) |
13,501 |
|
7% |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-03-03 |
4 |
S |
$242.37 |
$945,165 |
D/D |
(3,877) |
98,635 |
|
-5% |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
17,965 |
102,512 |
|
- |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2025-03-03 |
4 |
S |
$242.37 |
$114,820 |
D/D |
(471) |
28,011 |
|
-5% |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,137 |
28,482 |
|
- |
|
| Hesslein Robert W. |
EVP, CLO and Secretary |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
757 |
8,002 |
|
- |
|
| Poulton Jeffrey V. |
EVP, Chief Financial Officer |
• – – |
2025-03-03 |
4 |
S |
$242.37 |
$308,141 |
D/D |
(1,264) |
47,751 |
|
-5% |
|
| Poulton Jeffrey V. |
EVP, Chief Financial Officer |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,117 |
49,015 |
|
- |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-03 |
4 |
AS |
$242.37 |
$426,384 |
D/D |
(1,749) |
25,350 |
|
7% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,137 |
27,099 |
|
- |
|
| Fitzgerald Kevin Joseph |
CSO & EVP, Head of Research |
• – – |
2025-03-03 |
4 |
AS |
$242.37 |
$465,772 |
D/D |
(1,911) |
14,345 |
|
7% |
|
| Fitzgerald Kevin Joseph |
CSO & EVP, Head of Research |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,871 |
16,256 |
|
- |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-02-28 |
4 |
S |
$236.51 |
$700,894 |
D/D |
(2,900) |
84,547 |
|
-3% |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-02-28 |
4 |
S |
$236.51 |
$225,977 |
D/D |
(935) |
12,962 |
|
-3% |
|
| Fitzgerald Kevin Joseph |
CSO & EVP, Head of Research |
• – – |
2025-02-28 |
4 |
S |
$236.51 |
$119,878 |
D/D |
(496) |
12,385 |
|
-3% |
|
| Tanguler Tolga |
EVP, Chief Commercial Officer |
• – – |
2025-02-28 |
4 |
S |
$236.51 |
$123,983 |
D/D |
(513) |
14,345 |
|
-3% |
|
| Poulton Jeffrey V. |
EVP, Chief Financial Officer |
• – – |
2025-02-28 |
4 |
S |
$236.51 |
$192,390 |
D/D |
(796) |
33,898 |
|
-3% |
|
| Greenstreet Yvonne |
Chief Executive Officer |
• • – |
2025-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,921 |
87,447 |
|
- |
|
| Garg Pushkal |
CMO & EVP Dev & Med Affairs |
• – – |
2025-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,908 |
13,897 |
|
- |
|
481 Records found
|
|
Page 1 of 20 |
|
|
4.26 (1.67%) 
